A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease
Study sponsor: Denali Therapeutics Inc. · DNLI
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-08Estimated
Enrollment · participants32Estimated
Source updated2026-11-18Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.